Follow
Alexander Wyatt
Alexander Wyatt
Associate Professor, University of British Columbia
Verified email at prostatecentre.com - Homepage
Title
Cited by
Cited by
Year
Genomic hallmarks and structural variation in metastatic prostate cancer
DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ...
Cell 174 (3), 758-769. e9, 2018
7082018
Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer
AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ...
Clinical cancer research 21 (10), 2315-2324, 2015
5322015
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
4982018
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development
D Lin, AW Wyatt, H Xue, Y Wang, X Dong, A Haegert, R Wu, S Brahmbhatt, ...
Cancer research 74 (4), 1272-1283, 2014
4112014
Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer
AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ...
JNCI: Journal of the National Cancer Institute 109 (12), djx118, 2017
4072017
The master neural transcription factor BRN2 is an androgen receptor–suppressed driver of neuroendocrine differentiation in prostate cancer
JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ...
Cancer discovery 7 (1), 54-71, 2017
3882017
Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer
AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ...
JAMA oncology 2 (12), 1598-1606, 2016
3762016
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 …
DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ...
The Lancet Oncology 20 (12), 1730-1739, 2019
3262019
Mutations in BMP4 cause eye, brain, and digit developmental anomalies: overlap between the BMP4 and hedgehog signaling pathways
P Bakrania, M Efthymiou, JC Klein, A Salt, DJ Bunyan, A Wyatt, ...
The American Journal of Human Genetics 82 (2), 304-319, 2008
3022008
The placental gene PEG10 promotes progression of neuroendocrine prostate cancer
S Akamatsu, AW Wyatt, D Lin, S Lysakowski, F Zhang, S Kim, C Tse, ...
Cell reports 12 (6), 922-936, 2015
2822015
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
D Quigley, JJ Alumkal, AW Wyatt, V Kothari, A Foye, P Lloyd, R Aggarwal, ...
Cancer discovery 7 (9), 999-1005, 2017
2762017
The DNA methylation landscape of advanced prostate cancer
SG Zhao, WS Chen, H Li, A Foye, M Zhang, M Sjöström, R Aggarwal, ...
Nature genetics 52 (8), 778-789, 2020
2672020
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
N Lallous, SV Volik, S Awrey, E Leblanc, R Tse, J Murillo, K Singh, ...
Genome biology 17, 1-15, 2016
2452016
Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer
M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ...
European urology 72 (1), 34-42, 2017
2302017
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer
AV Lapuk, C Wu, AW Wyatt, A McPherson, BJ McConeghy, S Brahmbhatt, ...
The Journal of pathology 227 (3), 286-297, 2012
2192012
Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer
G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ...
European urology 75 (4), 667-675, 2019
1882019
Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer
G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ...
Clinical cancer research 23 (21), 6487-6497, 2017
1622017
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
AW Wyatt, ME Gleave
EMBO molecular medicine 7 (7), 878-894, 2015
1612015
Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials
MP Deek, K Van der Eecken, P Sutera, RA Deek, V Fonteyne, AA Mendes, ...
Journal of clinical oncology 40 (29), 3377-3382, 2022
1472022
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth
Y Yamamoto, Y Loriot, E Beraldi, F Zhang, AW Wyatt, NA Nakouzi, F Mo, ...
Clinical cancer research 21 (7), 1675-1687, 2015
1362015
The system can't perform the operation now. Try again later.
Articles 1–20